<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34688435</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-2619</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Respiratory medicine</Title><ISOAbbreviation>Lancet Respir Med</ISOAbbreviation></Journal><ArticleTitle>Waning immunity to SARS-CoV-2: implications for vaccine booster strategies.</ArticleTitle><Pagination><StartPage>1356</StartPage><EndPage>1358</EndPage><MedlinePgn>1356-1358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2213-2600(21)00458-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-2600(21)00458-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Faculty of Medicine, Hammersmith Hospital Campus, Imperial College London, London W12 0NN, UK. Electronic address: d.altmann@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyton</LastName><ForeName>Rosemary J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Hammersmith Hospital Campus, Imperial College London, London W12 0NN, UK; Lung Division, Royal Brompton &amp; Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/R02622X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S019553/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V036939/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/W020610/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Respir Med</MedlineTA><NlmUniqueID>101605555</NlmUniqueID><ISSNLinking>2213-2600</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet Respir Med. 2021 Dec;9(12):1450-1466. doi: 10.1016/S2213-2600(21)00407-0</RefSource><PMID Version="1">34688434</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>DMA and RJB receive support from the UK Medical Research Council (MR/S019553/1, MR/R02622X/1, MR/V036939/1, and MR/W020610/1) and the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre Institute for Translational Medicine and Therapeutics; Cystic Fibrosis Trust Strategic Research Centre (2019SRC015); NIHR Efficacy and Mechanism Evaluation Fast Track (NIHR134607); NIHR Long Covid (COV-LT2-0027); Innovate UK (SBRI 10008614); and Horizon 2020 Marie Sk&#x142;odowska-Curie Innovative Training Network European Training Network (no. 860325). Both authors are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec, outside of the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>20</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34688435</ArticleId><ArticleId IdType="pmc">PMC8530466</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00458-6</ArticleId><ArticleId IdType="pii">S2213-2600(21)00458-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dolgin E. COVID vaccine immunity is waning &#x2014; how much does that matter? Nature. 2021;597:606&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">34548661</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne G, Hames T, Scotton C, et al. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00407-0. published online Oct 21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00407-0</ArticleId><ArticleId IdType="pmc">PMC8530467</ArticleId><ArticleId IdType="pubmed">34688434</ArticleId></ArticleIdList></Reference><Reference><Citation>The Irish Times  Science uncertain about need for vaccine boosters, WHO says. Aug 18, 2021. https://www.irishtimes.com/news/health/science-uncertain-about-need-for-vaccine-boosters-who-says-1.4650435</Citation></Reference><Reference><Citation>Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26:1691&#x2013;1693.</Citation><ArticleIdList><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Swadling L, Gibbons JM, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol. 2020;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8101131</ArticleId><ArticleId IdType="pubmed">33361161</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med. 2021;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8253687</ArticleId><ArticleId IdType="pubmed">34250512</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch F, Weisblum Y, Barnes CO, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021;54:1853. 68.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8323339</ArticleId><ArticleId IdType="pubmed">34331873</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P, Kemp S, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021 published online Sept 6. 10.1038/s41586-021-03944-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Boyton RJ, Beale R. Immunity to SARS-CoV-2 variants of concern. Science. 2020;371:1103&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">33707254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385:1393&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo T, Rombauts A, Stadlbauer D, et al. Immunological imprinting of the antibody response in COVID-19 patients. Nat Commun. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213790</ArticleId><ArticleId IdType="pubmed">34145263</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>